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SUMMARY
Ubiquitin (Ub) and interferon-stimulated gene
product 15 (ISG15) reversibly conjugate to
proteins and mediate important innate antiviral
responses. The ovarian tumor (OTU) domain
represents a superfamily of predicted proteases
found in eukaryotic, bacterial, and viral proteins,
some of which have Ub-deconjugating activity.
Weshow that theOTUdomain-containingprote-
ases fromnairovirusesandarteriviruses, twoun-
relatedgroupsofRNAviruses, hydrolyzeUband
ISG15 from cellular target proteins. This broad
activity contrasts with the target specificity of
knownmammalianOTUdomain-containingpro-
teins. Expressionof a viral OTUdomain-contain-
ing protein antagonizes the antiviral effects of
ISG15 and enhances susceptibility to Sindbis
virus infection in vivo. We also show that viral
OTU domain-containing proteases inhibit NF-
kB-dependent signaling. Thus, the deconjugat-
ing activity of viral OTU proteases represents
a unique viral strategy to inhibit Ub- and ISG15-
dependent antiviral pathways.
INTRODUCTION
Viruses have evolved apanoply of differentmechanisms to
subvert cellular processes to their own advantage. In par-
ticular, viruses must overcome the potent antiviral and in-
flammatory effects of innate immune cytokines such as
type I interferon (IFNab) and tumor necrosis factor alpha
(TNFa). The induction and activity of these antiviral cyto-
kines is controlled by, among other factors, Ub and Ub-
like (UBL)molecules (Kirkin andDikic, 2007). Theactivation
of the transcriptional regulator nuclear factor-kB (NF-kB)
by TNFa was one of the first immune regulatory pathways
found to be dependent on protein ubiquitination (Karin and
Ben-Neriah, 2000). NF-kB is sequestered in the cytoplasm
of unstimulated cells through binding to IkB. TNFa binding
to its receptor induces IkB phosphorylation followed by
K48-linked poly-ubiquitination targeting IkB for proteaso-
mal degradation. This releases NF-kB dimers for translo-
cation to the nucleus, where they regulate transcription.
NF-kB-induced genes include type I IFN and other cyto-
kines, hence this Ub-controlled pathway plays a vital role
in innate and adaptive immunity, as well as in inflammation
(Tergaonkar, 2006). In addition toubiquitinationof IkB,K63-
and K48-linked ubiquitination regulates other molecules
involved in this signaling pathway (Chen, 2005).
ISG15 is an interferon-induced UBL molecule with im-
portant antiviral activity against Sindbis, herpes simplex,
influenza A, and influenza B viruses (Lenschow et al.,
2007). ISG15, like Ub, is covalently conjugated to target
proteins via a C-terminal LRLRGG sequence (Haas
et al., 1987; Loeb and Haas, 1992; Narasimhan et al.,
1996). Although conjugation is critical for the antiviral
activity of ISG15 (Lenschow et al., 2005, 2007), the mech-
anism by which ISG15 mediates its antiviral function is not
completely understood.
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Ub and ISG15 are synthesized as inactive precursors
with C-terminal extensions that undergo cleavage to
reveal the motif required for conjugation. Coordinated ac-
tivities of an enzymatic cascade comprising an activating
enzyme (E1), a conjugating enzyme (E2) and a ligase (E3)
result in the conjugation of Ub or ISG15 to the 3-amino
group of a lysine residue present in the target protein.
Both Ub and ISG15 conjugation can be reversed by the
activity of deconjugating enzymes. Deubiquitinating
(DUB) proteolytic enzymes are also involved in processing
of Ub precursors. Five classes of DUBs have been
described (Nijman et al., 2005); one of the most recently
identified is the ovarian tumor (OTU) domain family. This
family comprises a group of putative cysteine proteases,
homologous to the OTU protein in Drosophila, and in-
cludes more than a hundred proteins from eukaryotes,
bacteria, and viruses (Makarova et al., 2000). Several
OTU domain-containingmammalian proteins, such asCe-
zanne (Evans et al., 2003), Otubain 1 and 2 (Balakirev et al.,
2003), and A20 (Evans et al., 2004) have been identified as
proteases that participate in substrate-specific deubiquiti-
nating processes. For example, A20 is an important down-
regulator of TNFa signaling via its deubiquitination of
TRAF6 (Boone et al., 2004) and its dual function of poly-
Ub63 deconjugation followed by poly-Ub48 modification
of RIP (Wertz et al., 2004). These activities are mediated
by its N-terminal OTU domain and its C-terminal zinc fin-
ger domain, respectively. However, the substrate speci-
ficity and physiologic role of most OTU domain-
containing proteins remains unknown.
As protein ubiquitination and ISGylation are both impor-
tant for innate immunity, rely on terminal LRLRGG se-
quences, and share a commonmechanismof conjugation,
we tested the hypothesis that viral OTU domain-contain-
ing proteases regulate Ub- and ISG15-dependent innate
immunity via deconjugating protease activity. We found
that two unrelated families of RNA viruses express OTU
domain-containing proteases with the capacity to de-
crease Ub and ISG15 conjugation. Nairoviruses are nega-
tive-sense, segmented, RNA viruses of the Bunyaviridae
family. Their large (L) protein contains an OTU domain
and an RNA polymerase domain, placing this protein in
the growing category of multifunctional viral proteins.
Crimean Congo hemorrhagic fever virus (CCHFV) is a
human nairovirus that causes hemorrhagic fever with up
to 30%mortality (Whitehouse, 2004). Arteriviruses, includ-
ing equine arteritis virus (EAV) and porcine respiratory and
reproductive syndrome virus (PRRSV), are the causative
agents of important diseases in horses and pigs. They
are positive-sense, nonsegmented RNA viruses that con-
tain an OTU domain within their nonstructural protein 2
(nsp2), which is also involved in viral replicase polyprotein
processing (Snijder et al., 1995). We found that these viral
OTU domains, in contrast to known mammalian OTU
proteases, display a broad deconjugating activity toward
ubiquitinated and ISGylated products and consequently
inhibit innate immunity pathways that are dependent on
Ub and ISG15. Thus, the deconjugating activity of viral
OTU domains represents a unique strategy used by nairo-
viruses and arteriviruses to evade the host antiviral
response, probably by targeting a common biochemical
structure in Ub and the UBL protein ISG15.
RESULTS
OTU Domains in Viral and Mammalian Proteins
Sequencing of the L gene of the highly pathogenic human
virus CCHFV (NFS and AGS, data not shown) (Honig et al.,
2004; Kinsella et al., 2004) led to the identification of an
OTU domain in the N-terminal region of the viral protein
(Figure 1). This domain was also present in the L proteins
of the nairoviruses Dugbe virus (DUGV) and Nairobi sheep
disease virus (Honig et al., 2004) but has not been found in
the L proteins of any other genus in the Bunyaviridae
Figure 1. The OTU Domain Sequence Is Conserved across Viral and Mammalian Proteins
Multiple alignment of the OTU domains present in the proteins used in this study. In the consensus (Makarova et al., 2000), ‘‘h’’ indicates hydrophobic
residues (A, C, F, L, I, M, V, W, Y, T, S, G), ‘‘s’’ indicates small residues (A, C, S, T, D, V, G, P), ‘‘+’’ indicates positively charged residues (R, K), ‘‘a’’
indicates aromatic residues (W, Y, F, H), and ‘‘t’’ indicates residues with high b-turn-forming propensity (A, C, S, T, D, E, N, V, G, P). Highly conserved
residues are shaded in black. Numbers at the beginning and end of each sequence indicate the positions of the first and last aligned residue in the
respective protein sequences; the numbers between aligned blocks indicate the numbers of residues that are not shown. CCHFV, Crimean Congo
hemorrhagic fever virus; DUGV, Dugbe virus; EAV, equine arteritis virus; PRRSV, porcine respiratory and reproductive syndrome virus; VCIP,
VCIP135; Cez, Cezanne; OTUB1 and OTUB2, Otubains 1 and 2, respectively.
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family. An alignment of the OTU domains present in nairo-
viruses, arteriviruses, and mammalian proteins A20,
Cezanne, VCIP135, Otubain 1, andOtubain 2 revealed lim-
ited identity; however, a strong conservation of D37, G38,
N39, C40,W71, H151, and an aromatic amino acid at position
152 (numbering based on the CCHFV-L sequence) was
observed (Figure 1, black boxes). Among these amino
acids, C40 and H151 (Figure 1, black arrows) were pre-
dicted to be the catalytic residues present in the putative
protease active site (Balakirev et al., 2003; Makarova
et al., 2000; Nanao et al., 2004; Snijder et al., 1995).
Impact of CCHFV-L Expression on Protein
Ubiquitination and ISGylation
Given that host OTU domain proteins have deubiquitinat-
ing activity (Nijman et al., 2005), we tested the hypothesis
that the L protein of CCHFV (CCHFV-L) has deubiquitinat-
ing and deISGylating activity (Figure 2). Transfection of
Figure 2. Levels of Ubiquitinated and ISGylated Proteins in Cells Expressing CCHFV-L and CCHFV-L Mutants
(A) Schematic representation of the CCHFV-L constructs utilized in these studies. Predicted protein domains within the protein: OTU domain; ZF, zinc
finger; LZ, leucine zipper; RdRp, RNA-dependent RNA polymerase conserved motifs. White stars represent mutations in the OTU domain: 1A (C40A)
or 2A (C40A and H151A). All constructs were HA tagged.
(B) 293T cells were transfected with either HA-Ub (panel A) or His-ISG15, HA-mUBE1L, and Flag-UbcM8 (panels B–D) along with HA-tagged
CCHFV-L constructs, Flag-UBP43, or empty plasmid. Total protein ubiquitination was visualized by immunoblotting with anti-HA (panel A), and pro-
tein ISGylation was visualized by anti-ISG15 immunoblot (panel B). ISG15-transfected samples were also probed with anti-HA or anti-Flag (panels C
and D) for detection of the CCHFV-L constructs (left arrows), mUbE1L, UBP43 (inset), and UbcM8. Asterisk indicates a nonspecific band.
(C) L and L 1A were analyzed for their effect on total ubiquitination (panel A) or ISGylation (panel B) as described in (B). Expression of HA-tagged
UBE1L (panel C), L and L 1A (panel D), and L(1–169) and L(1–169)2A (panel E) is shown.
406 Cell Host & Microbe 2, 404–416, December 2007 ª2007 Elsevier Inc.
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cells with plasmids expressing CCHFV-L slightly de-
creased the overall expression of Ub-conjugated proteins
(Figure 2B, lanes 1 and 2, panel A; Figure 2C, lanes 1, 4,
and 5, panel A). To test the effect of CCHFV-L expression
on protein ISGylation, ISG15 conjugates were generated
by transfecting plasmids expressing ISG15 and its specific
E1 (UBE1L) (Yuan and Krug, 2001) and E2 (UbcM8) (Kim
et al., 2004; Zhao et al., 2004) enzymes, since endogenous
levels of ISGylated proteins are low in the absence of IFN
stimulation. Cotransfection of CCHFV-L resulted in a clear
decrease in the level of ISGylated proteins (Figure 2B,
lanes 1 and 2, panel B; Figure 2C, lanes 1, 4, and 5, panel
B). This decrease was also observed when CCHFV-L was
untagged (data not shown). The decrease in total ISGyla-
tion was comparable to the effect of UBP43, a known
ISG15 deconjugating enzyme (Figure 2B, lane 9, panel B).
Expression of CCHFV-L did not affect levels of expression
of UBE1L or UbcM8 (Figure 2B, lane 2, panels C and D;
Figure 2C, lanes 4 and 5, panel C), consistent with
CCHFV-L acting via inhibition of ubiquitination and ISGyla-
tion reactions or by directly deubiquitinating or deISGylat-
ing proteins.
The OTU Domain of CCHFV-L Decreases
the Levels of Ubiquitinated
and ISGylated Proteins
To determine the region of the L protein responsible for
decreasing ubiquitinated and ISGylated proteins, plas-
mids expressing three portions of the L protein were
constructed (Figure 2A). Expression of the OTU domain-
containing N-terminal portion, L(1–1325), resulted in the
greatest decrease of Ub and ISG15 conjugates (Fig-
ure 2B, lane 3, panels A and B). To further map this
region, truncation mutants of the L protein expressing
only the first 354, L(1–354), or 169 amino acids, L(1–
169), were tested. The results indicated that the region
responsible for the decreased levels of Ub and ISG15
conjugates mapped to the OTU domain, L-(1–169) (Fig-
ure 2B, lanes 6 and 7, panels A and B; Figure 2C, lane
2, panels A and B).
The Predicted Protease Active Site of the
CCHFV-L OTU Domain Is Required for Reducing
Ub and ISG15 Conjugates
To test whether the amino acids C40 and H151 (Figure 1,
black arrows) were critical for the observed reduction in
ubiquitinated and ISGylated proteins by the CCHFV-L
OTU domain, we expressed a full-length L protein with
a C40 to A40 mutation (L 1A) and a mutant L(1–169) protein
in which both amino acids were replaced by alanines
[L(1–169)2A] (Figure 2A). Expression of L 1A and L(1–
169)2A proteins did not decrease levels of ubiquitinated
or ISGylated proteins (Figure 2B, lane 8, panels A and B;
Figure 2C, lanes 3, 6, and 7, panels A and B), strongly sug-
gesting that the OTU domain contains a cysteine protease
activity that mediates the decrease in ubiquitinated and IS-
Gylated proteins.
The OTU Domain of CCHFV-L Is a Deconjugating
Enzyme with Specificity for Poly-Ub Conjugates
and ISG15
To determine whether the CCHFV-L OTU domain directly
deconjugates Ub and ISG15 from target proteins, we ex-
pressed and purified L(1–169) and a catalytic C40 to A40
mutant, L(1–169)1A, for in vitro deconjugation assays (Fig-
ure 3A). Recombinant L(1–169) cleaved both K48- and K63-
linked poly-Ub chains into monomers (Figure 3B, lanes 2
to 5), similarly to isopeptidase T, a known DUB enzyme
(Figure 3B, lane 10). This activity was markedly decreased
by mutating the amino acid C40 (Figure 3B, lanes 6 to 9),
indicating that this residue is required for optimal protease
activity. The small amount of deconjugation observed with
L(1–169)1A is not unexpected, as mutation of Cezanne’s
catalytic cysteine yielded similar data where most, but
not all, catalytic activity was impaired (Evans et al.,
2003). This result shows that the OTU domain of
CCHFV-L has bona fide DUB activity in the absence of
other cellular proteins.
We next determined whether L(1–169) can deconju-
gate ISGylated proteins. For this, we generated cell ly-
sates from IFNb-treated Ubp43/ murine embryonic fi-
broblasts (MEFs) that are rich in ISG15 conjugates
(Malakhov et al., 2003). Incubation of these lysates with
recombinant L(1–169) protein, but not L(1–169)1A, appre-
ciably decreased ISGylated proteins (Figure 3C, top
panel) in a L(1–169) concentration-dependent manner.
This result suggests that the CCHFV OTU domain has
C40-dependent ISG15 deconjugating activity but does
not exclude the possibility that the protease activity of
the viral OTU domain was activating another deISGylat-
ing enzyme present in cell lysates. To address this possi-
bility, we enriched 6xHisISG15 conjugates using affinity
chromatography. Incubation of ISG15 conjugates with in-
creasing amounts of L(1–169) resulted in ISG15 deconju-
gation (Figure 3C, lanes 2 to 5, bottom panel). No decon-
jugation was detected with the mutant L(1–169)1A
protein (Figure 3C, lanes 6 to 9, bottom panel). In addi-
tion, L(1–169) processed a pro-ISG15 protein into its ma-
ture form (Figure 3E, lane 2, panel A). These data suggest
that the CCHFV-L OTU domain directly deconjugates IS-
Gylated proteins through its predicted cysteine protease
activity.
To gain further insights on the specificity of the OTU do-
main, we assessed the ability of L(1–169) and L(1–169)1A
to hydrolyze poly-SUMO-2 (Figure 3D, top panel) and
poly-SUMO-3 chains (Figure 3D, bottom panel), pro-
SUMO-1 (Figure 3E, panel C), and pro-Nedd8 (Figure 3E,
panel B). While the catalytic domain of SENP2 (SENP2CD),
a SUMO-specific protease, could hydrolyze SUMOchains
to monomers (Figure 3D, lane 10) and process pro-
SUMO-1 (Figure 3E, lane 5, panel C), neither L(1–169)
nor L(1–169)1A was able to cleave SUMO chains or
a pro-SUMO-1 precursor. However, similar to its ability
to process pro-ISG15 (Figure 3E, lane 2, panel A), L(1–
169) hydrolyzed pro-Nedd8 into a mature form (Figure 3E,
lane 2, panel B). In summary, theOTU domain of CCHFV-L
hydrolyzes Ub and ISG15, but not SUMO-2 or SUMO-3,
Cell Host & Microbe 2, 404–416, December 2007 ª2007 Elsevier Inc. 407
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from conjugates in vitro, suggesting that viral OTU do-
mains have the unique ability to recognize Ub and specific
UBL molecules.
Additional Viral OTU Domains Mediate
Deubiquitination and DeISGylation
In addition to CCHFV, viral OTU domains are found in the L
proteins of other nairoviruses and in the nsp2 proteins of
arteriviruses such as EAV and PRRSV (Figure 1). The arter-
ivirus nsp2 cysteine protease cleaves the nsp2/nsp3 site
within the large viral polyprotein during replicase matura-
tion. In the case of EAV, this process is known to be medi-
ated by the 166 N-terminal residues of nsp2, which
contains the OTU domain (Snijder et al., 1995). In our
study, a slightly larger N-terminal EAV-nsp2 domain
(175 amino acids; nsp2N) was used in addition to the full-
length protein. The OTU domain of the L protein of DUGV,
a nairovirus related to CCHFV, as well as EAV-nsp2,
EAV-nsp2N, and PRRSV-nsp2, decreased Ub and ISG15
conjugates when expressed in 293T cells (Figure 4A, lanes
3–6), indicating that deconjugation may be an immune
evasion strategy shared by diverse viral families.
Previous studies have demonstrated that the OTU do-
main-containing mammalian proteins Otubain 1, Otubain
2, Cezanne, VCIP135, and A20 cleave poly-Ub chains
in vitro (Balakirev et al., 2003; Evans et al., 2003, 2004;
Wang et al., 2004). In contrast, only overexpression ofOtu-
bain 1 and Cezanne moderately decreased cellular global
Ub conjugate levels, while expression of A20 or Otubain
2 had no effect on total levels of ubiquitinated proteins (Ba-
lakirev et al., 2003; Evans et al., 2003, 2004). To date, there
have been no published studies investigating the effects of
these proteins on ISG15 conjugates. We therefore tested
Otubain 1, Otubain 2, Cezanne, VCIP135, and A20 for their
Figure 3. In Vitro Ub and ISG15 Deconjugation Activities of the CCHFV-L OTU Domain
(A) Coomassie-stained gel of GST-L(1–169), L(1–169), GST-L(1–169)1A, and L(1–169)1A recombinant proteins. L(1–169) and L(1–169)1A proteins
were used for the in vitro experiments.
(B) K48 (top panel)- or K63 (bottom panel)-linked poly-Ub chains were incubated with reaction buffer (lane 1) or 10-fold dilutions of L(1–169) or L(1–
169)1A recombinant proteins, subjected to SDS-PAGE and visualized by Coomassie staining. Isopeptidase T (IsoT) was used as a positive control.
Black arrows indicate L(1–169) and L(1–169)1A proteins.
(C) Lysates of Ubp43/ MEFs (top panel) or ISG15 conjugates purified from ISG15, HA-mUBE1L, and Flag-UbcM8 transfected 293T cells (bottom
panel) were incubated with reaction buffer (lane 1) or 10-fold dilutions of L(1–169) or L(1–169)1A protein. ISG15 conjugates were visualized by anti-
ISG15 immunoblot.
(D) SUMO-2 (top panel) or SUMO-3 (bottom panel) chains were incubated with reaction buffer (lane 1) or 10-fold dilutions of L(1–169) or L(1–169)1A
and visualized by Coomassie staining. His6-SENP2CD was used as a positive control. Black arrows indicate L(1–169) and L(1–169)1A proteins. S2–8
indicates number of SUMO-2 or SUMO-3 molecules.
(E and F) ProISG15 (panel A), proNedd8 (panel B), proSUMO-1 (panel C) or K48-linked Ub (F) chainswere incubated with reaction buffer, L(1–169), L(1–
169)1A, or A20 catalytic domain (A20CD) and visualized by Coomassie staining. Positive controls indicate incubation with UBP43 (panel A), NEDP1
(panel B), SENP2CD (panel C), or IsoT (F). Black arrows indicate L(1–169) and L(1–169)1A proteins, and white arrowhead indicates A20CD. ‘‘Pro’’ in-
dicates the pro-UBL molecule form, and ‘‘Mat’’ indicates the mature protein.
408 Cell Host & Microbe 2, 404–416, December 2007 ª2007 Elsevier Inc.
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ability to decrease overall protein ubiquitination and ISGy-
lation in transfected cells (Figure 4B). Expression of Otu-
bain 1 resulted in a significant decrease in Ub conjugate
levels, while Otubain 2 and Cezanne had a lesser effect
(Figure 4B, lanes 2–4, panel 1). Consistent with their spec-
ificity for particular ubiquitinated substrates, expression of
VCIP135 and A20 did not result in a decrease in overall
ubiquitination. None of the OTU-containing mammalian
proteins tested decreased global levels of ISG15 conju-
gates (Figure 4B, lanes 2–6, panel 2). Similar results
were obtained when truncation mutants expressing the
OTU domains of Otubain 1, Otubain 2, Cezanne, and
A20 were tested (data not shown). In addition, the OTU-
containing catalytic domain of A20 (A20CD) was unable
to process either ISG15 or Nedd8 (Figure 3E, lane 4,
panels A and B), even though it cleaved K48-linked Ub
chains (Figure 3F, lane 4). By contrast, overexpression of
the mammalian deISGylating enzyme UBP43 decreased
overall levels of ISG15 conjugates but not Ub conjugates
(Figure 4B, lane 7). Thus, viral OTU proteases appear to
be unique in their ability to target both ISG15 and Ub con-
jugates.
Transgenic Mice Expressing CCHFV-L(1–1325)
Have Increased Susceptibility to Sindbis
Virus Infection
To assess the effect of expressing an OTU domain during
viral infection, we generated transgenic mice expressing
the CCHFV-L(1–1325) OTU domain-containing protein,
which exhibits DUB and deISGylating activities
(Figure 2B, lane 3). We obtained germline transgene trans-
mission in three lines designated 1836, 1854, and 2929,
and we evaluated L(1–1325) expression in both MEFs
and brain lysates from these transgenic lines. MEF
cells and brain tissue from 1836 transgenic mice con-
tained detectable L(1–1325) protein, while protein expres-
sion from the 1854 and 2929 lines was either undetectable
or very low (Figures 5A and 5B). We next evaluated the
Figure 4. Ub and ISG15 Deconjugation Activity of OTU Domain-Containing Polypeptides of Viral and Mammalian Origin
(A) CCHFV-L(1–169), DUGV-L(1–169), PPRSV-nsp2, EAV-nsp2N, or EAV-nsp2 were cotransfected into 293T cells with either HA-Ub (panel 1) or
ISG15, HA-mUBE1L, Flag-UbcM8, and Herc5 plasmids (panels 2 and 3). Samples were immunoblotted for HA (panel 1) or ISG15 (panel 2).
ISG15-transfected samples were also probed with anti-HA (panel 3) or anti-Flag plus anti-HA (panel 4) to show expression of HA-mUBE1L,
PPRSV-nsp2, CCHFV-L(1–169), DUGV-L(1–169), EAV-nsp2N, or EAV-nsp2 (inset, open triangle). Asterisk indicates a nonspecific band.
(B) Otubain 1, Otubain 2, Cezanne, VCIP135, A20, or UBP43were analyzed for their effect on total ubiquitination (panel 1) or ISGylation (panels 2–4) as
described in (A). Expression of HA-tagged Cezanne and VCIP135 (panel 3) and Flag-tagged Otubain 1 and 2 and UBP43 (panel 4) is shown.
Cell Host & Microbe 2, 404–416, December 2007 ª2007 Elsevier Inc. 409
Cell Host & Microbe
Evasion of Ubiquitin- and ISG15-Dependent Immunity
sensitivity of L(1–1325) transgenic mice to infection with
the virulent Sindbis virus strain AR86, an alphavirus that
causes lethal encephalitis in young mice and is sensitive
to ISG15-mediated antiviral effects (Lenschow et al.,
2005). Susceptibility to Sindbis virus infection tracked
with expression of the L(1–1325) protein (Figure 5C).
Thirty-five percent of mice from the 1836 transgenic
line survived infection compared to R80% survival in
C57/BL6 littermate controls or transgenic mice express-
ing low or undetectable levels of transgene-encoded
protein. The decreased survival of line 1836 transgenic
mice following AR86 infection suggests that CCHFV-L
OTU enhances susceptibility to viral disease in vivo.
The OTU Domain of CCHFV Overcomes
ISG15-Mediated Protection from Sindbis
Virus-Induced Lethality
The increased pathogenicity of Sindbis virus observed in
L(1–1325)-expressing mice suggested that the CCHFV-L
OTU domain might counteract the antiviral activities of
ISG15 in vivo. It was previously shown that expression
of ISG15 from the chimeric Sindbis virus dsTE12Q pro-
tects adult IFNabR/ mice from Sindbis virus-induced
lethality (Lenschow et al., 2005). To determine whether ex-
pression of the CCHFV-L OTU domain would antagonize
this protective effect of ISG15, we engineered four
recombinant chimeric Sindbis viruses (Figure 6A). Two
viruses expressed ISG15 followed by an IRES element
to drive translation of either L(1–169) (169GG) or enzymat-
ically inactive L(1–169)2A (MTGG). We also generated
control viruses that expressed either L(1–169) (169) or
L(1–169)2A (MT) in the absence of ISG15.
The recombinant viruses expressed the OTU domains
and ISG15 as expected (Figures S1A and S1B in the Sup-
plemental Data available with this article online) as well as
similar levels of Sindbis virus proteins in infected cells
(Figure S1C). All four viruses grew with similar kinetics to
similar final titers under single-step growth conditions in
BHK-21 cells (Figure S2). This is expected, as to date
ISG15 has only demonstrated antiviral activity in vivo.
We assessed the ability of the L(1–169) protein ex-
pressed from within the Sindbis virus genome to deISGy-
late and deubiquitinate proteins by infecting BHK-21 cells
(Figure 6B). Infection with 169GG or 169, but not MTGG or
MT, reduced the amount of Ub conjugates detected in
cells (Figure 6B, right panel), indicating that the viral OTU
domain functions as a DUB enzyme when expressed
from a Sindbis virus. Following transfection with ISG15
and its E1, E2, and E3 enzymes, ISGylated proteins can
be detected in BHK-21 cells (Figure 6B, lane 1, middle
panel). Infection with 169GG or 169 greatly reduced
ISG15 conjugates, confirming that OTU expression results
in deconjugation of ISGylated proteins. When cells were
transfected with the E1, E2, and E3 enzymes but not
ISG15, ISG15 conjugates were observed only following
MTGG infection (Figure 6B, left panel). This shows that
ISG15 expressed from dsTE12Q is capable of ISGylating
proteins in the presence of the relevant conjugating
enzymes but that this is only seen in the presence of a
catalytically inactive form of the coexpressed L(1–169)
protein (Figure 6B, lane 3, left panel).
We then determined whether OTU expression could
counter ISG15’s in vivo antiviral effect. In order to exclude
effects due to IFNab-stimulated genes other than ISG15,
we infected IFNabR/mice (Figure 6C). Seventy percent
of mice infected with a virus expressing ISG15 and the
mutant OTU domain (MTGG) survived, consistent with
previous observations that expression of ISG15 protects
mice from lethality following Sindbis virus infection (Len-
schow et al., 2005). In contrast, only 20% of mice infected
with a virus expressing ISG15 and a functional OTU do-
main (169GG) survived infection (p = 0.0015). These data
also correlate with our in vitro data demonstrating that
L(1–169), but not L(1–169)2A, can deISGylate proteins
following infection (Figure 6B). Mice infected with 169 or
MT died with similar kinetics, demonstrating that the
expression of L(1–169) did not increase the virulence of
dsTE12Q in the absence of the IFN-mediated antiviral
response. The slight increase in survival between 169GG
and 169 (p < 0.0001) or MT (p = 0.0032) suggests that
Figure 5. Expression of L(1–1325) Transgene Correlates with Increased Susceptibility to Sindbis Virus Infection
(A and B) Expression of L(1–1325) transgene and actin in MEFs (A) and brain lysates (B). + indicates a transgene-positive mouse, and  indicates
a C57/BL6 mouse. The arrows indicate L(1–1325) protein and open triangles denote actin.
(C) Survival of L(1–1325) transgenic mice following infection with Sindbis virus AR86. Transgene-negative littermates from 1836, 1854, and 2929
served as C57/BL6 controls. Numbers of mice in each group are indicated in parenthesis. Comparison by statistical analysis was made between
1836+ and C57/BL6 (p = 0.0011).
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expression of the CCHFV OTU domain cannot completely
antagonize the effects of ISG15 in this system. Neverthe-
less, these data show that expression of a catalytically ac-
tive viral OTU domain can antagonize the antiviral effects
of ISG15 in vivo.
Negative Regulation of the NF-kB Pathway
by Viral OTU Domains
While the data above indicate that a viral OTU domain
protease can counter the antiviral activities of ISG15,
they do not address the possibility that the DUB activity
of these proteins might also play a role in immune
evasion. To address this hypothesis, we evaluated the
effects of the CCHFV-L and EAV-nsp2 OTU domains on
the NF-kB signaling pathway. Expression of the OTU
domains of CCHFV-L and of EAV-nsp2 decreased in
a dose-dependent manner the activation of an NF-kB-
responsive promoter (Fujita et al., 1992) after TNFa treat-
ment. This inhibition was similar to that mediated by A20,
an OTU domain-containing inhibitor of the NF-kB path-
way (Figure 7A). Inhibition was about 10-fold greater in
the presence of the L(1–169) domain than the L(1–
169)2A mutant, indicating a role for the OTU domain pro-
tease activity. These results were further confirmed by
the ability of CCHFV-L(1–169) to inhibit NF-kB activation
as measured by the inhibition of endogenous p65 nuclear
translocation upon TNFa treatment (Figures 7B and 7C).
The slight inhibition of NF-kB activation by the L(1–
169)2A protein could be caused by some residual binding
of this mutant to ubiquitinated substrates or by the pres-
ence of some other regulatory motifs within this protein.
Nevertheless, the p65 nuclear translocation inhibition by
the L(1–169) protein was significantly higher when com-
pared to its mutant counterpart (p = 0.0044). Overall,
these results demonstrate the ability of viral OTU
domains to affect immune pathways that are regulated
by ubiquitination.
DISCUSSION
Here we show that viral OTU domain-containing proteins
are proteases that hydrolyze Ub and ISG15 from conju-
gated proteins. This dual deconjugating activity provide
an elegant example of the economy of viral evolution,
since both Ub and ISG15 rely on a conserved conjugation
motif. Furthermore, the protease activity by the viral OTU
domains has the physiologic capacity to evade two differ-
ent cytokine pathways, IFNab and TNFa, that are funda-
mentally important for antiviral immunity.
Figure 6. Sindbis Viruses Expressing the CCHFV-L OTU Domain Deconjugate Ub and ISG15 and Inhibit ISG15-Mediated Antiviral
Effects in Mice
(A) Schematic diagram representing the CCHFV OTU domain-expressing Sindbis viruses utilized in these studies. G, genomic promoter; SG, sub-
genomic promoter.
(B) BHK-21 cells were transfected with UBE1L, UbcM8, and Herc5 (left panel), UBE1L, UbcM8, Herc5, and ISG15 (middle panel), or HA-Ub (right
panel) and subsequently infected with recombinant Sindbis viruses as indicated. Cells lysates were immunoblotted with anti-ISG15 (left and middle
panels) or anti-HA (right panel) antibodies.  indicates untransfected cells.
(C) IFNabR/mice were infected with recombinant Sindbis viruses as indicated and monitored for survival. Data are pooled from four independent
experiments, and numbers of mice in each group are indicated in parenthesis. Differences in survival were analyzed by the log-rank test: 169GG and
169 (p < 0.0001), 169GG and MT (p = 0.0032), 169GG and MTGG (p = 0.0015), MTGG and 169 (p < 0.0001), and MTGG and MT (p < 0.0001).
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Viral DUB and DeISGylating Enzymes: A Unique
Strategy for Immune Evasion?
Biochemical and genetic evidence supports the concept
that protein ubiquitination plays a critical role in the induc-
tion of both the innate and the adaptive cellular immune
system (Liu et al., 2005). For example, in addition to NF-
kB signaling, Ub regulates several aspects of antiviral
immunity, such as MHC class I and II antigen presentation
(Loureiro and Ploegh, 2006; Shin et al., 2006), TLR/IL1
signaling (Chen, 2005), and induction of type I IFN by the
cellular viral sensor RIGI (Gack et al., 2007). Inhibition of
protein ubiquitination might also affect other cellular pro-
cesses that can be subverted by viruses for their own
advantage, such as the proteasome-mediated protein
degradation system, multiple signal transduction events,
or cell cycle progression. Given the effects that we ob-
served on NF-kB signaling, it seems likely that viral OTU
domain-containing proteases may be able to target these
and other Ub-dependent pathways.
While the biochemical effects of ISGylation have been
studied far less extensively than those of Ub, ISG15 is an
important antiviral protein (Lenschow et al., 2005, 2007;
Okumura et al., 2006). Thus, it is not surprising that viruses
may use multiple strategies to counter the antiviral effects
of ISG15. Theworkpresentedhereprovidesa viral strategy
for decreasing expression of bona fide ISG15 conjugates
in cells. The first such strategy reported is the direct asso-
ciation of the NS1 protein of influenza B virus with ISG15.
This association inhibits protein ISGylation by blocking
the ISG15-UBE1L interaction (Yuan et al., 2002; Yuan
Figure 7. CCHFV-L and EAV-nsp2 OTU Domains Inhibit TNFa-Mediated NF-kB Activation
(A) NF-kB reporter assay in 293T cells transfected with OTU domains and treated with TNFa. Results shown are an average of three independent
experiments. The western blot indicates expression of viral OTU proteins as detected with anti-HA [CCHFV-L(1–169) and CCHFV-L(1–169)2A] or
anti-Flag antibodies (EAV-nsp2N). E, empty plasmid.
(B) A549 cells were transfected with indicated plasmids, stimulated with TNFa, and stained for p65 (red) and L(1–169) or L(1–169)2A (green). Nuclei
were stained with DAPI (blue). The result shown is a representative of three independent experiments.
(C) L(1–169) or L(1–169)2A transfected cells in (B) were scored according to subcellular distribution of p65. Differences in p65 nuclear accumulation in
TNFa-treated cells were analyzed by Student’s t test: E and L(1–169) (p < 0.0001), E and L(1–169)2A (p = 0.0007), and L(1–169) and L(1–169)2A
(p = 0.0045). E, empty plasmid. The result shown is a representative of three independent experiments.
Data in (A) and (C) are presented as mean ± SD (n = 3).
412 Cell Host & Microbe 2, 404–416, December 2007 ª2007 Elsevier Inc.
Cell Host & Microbe
Evasion of Ubiquitin- and ISG15-Dependent Immunity
and Krug, 2001), while the viral OTU domain proteases an-
alyzed here accomplish a similar effect via deconjugation.
The Ub and ISG15 deconjugation activities by the viral
OTU domains contrast with the specific Ub deconjugation
activity by the OTU domain-containing cellular proteins
tested in this study. We speculate that other viral prote-
ases, perhaps including some that do not have OTU do-
mains, will be found to target both Ub- and ISG15-depen-
dent processes. To date, viral DUB activities and in vitro
cleavage of ISG15 fusion proteins have been demon-
strated for the adenoviral protease adenain (Balakirev
et al., 2002) and the papain-like proteases from the severe
acute respiratory syndromecoronavirus (SARS-CoV) (Bar-
retto et al., 2005; Lindner et al., 2005; Ratia et al., 2006).
OTU Domain Specificity and Deconjugating
Activity, a Target for Antiviral Drug Development?
We found that the CCHFV-L OTU domain processed Ub
and ISG15 conjugates and pro-ISG15 and pro-Nedd8
in vitro but did not have activity against any SUMO
isoforms. Ub, ISG15, and Nedd8 differ from SUMO in their
exposed C-terminal motifs: LRLRGG for Ub and ISG15
and LALRGG for Nedd8 versus QQQTGG for SUMO-2
and SUMO-3. This raises the interesting possibility that
sequences similar to the LRLRGG motif may play an
important role in substrate recognition and specific cleav-
age by CCHFV-L OTU and perhaps other viral proteases.
Interestingly, the nsp2 of arteriviruses cleaves the nsp2/3
junction at FRLIGG (EAV) or GRLLGG (PRSSV) (Allende
et al., 1999; Snijder et al., 1996; Ziebuhr et al., 2000),
sequences similar to the LRLRGG motif. Thus, arterivirus
OTU proteases have dual functions: performing essential
viral polyprotein processing and targeting host substrates
to modulate the antiviral response. This is analogous to
the hepatitis C virus NS3-4A protease, which is involved
both in viral polyprotein processing and in cleaving the
cellular antiviral proteins TRIF and IPS-1 (Li et al., 2005;
Lin et al., 2006).
The characterization of the CCHFV-L OTU domain and
the development of in vitro assays for its enzymatic activi-
ties as described in this studywillmake it feasible to screen
for potential inhibitors specific forCCHFV-L andotherOTU
domain-containing viral proteins.High-throughput screen-
ingof chemical compound librarieshasproven tobeavalu-
able tool in the identification of small-molecule inhibitors of
other viral proteases such as HCV-NS3-4A (Sudo et al.,
2005) and SARS-3CLpro (Blanchard et al., 2004). Since
the viral OTU domains have a unique capacity to target
both Ub and ISG15 conjugates, the design of specific
inhibitors might be possible. For this reason, structural
studieswill be of great value to understandboth themolec-
ular basis of the unique biochemical activities of these viral
proteins and the potential for development of antiviral
compounds.
Physiologic Importance of Viral OTU Domain
Protease DUB and DeISGylating Activities
Our demonstration that viral OTU domain-containing
proteases can decrease both Ub and ISG15 conjugates
in cells does not alone constitute proof that protease ac-
tivity directed toward these substrates plays a role in viral
infection. We were limited in performing the obvious
experiment of assessing the role of viral OTU domain pro-
tease activity during infection by two things. First, CCHFV
is a biosafety level 4 pathogen lacking a good animal
model and whose molecular biology is not well enough
developed to allow generation of mutant viruses. Second,
the viral OTU domain proteases evaluated here either
have, or are likely to have, important effects on processing
of viral polyproteins (see above). Given this, we felt that it
would be difficult to prove that these proteases have ef-
fects during infection that are solely attributable to their
DUB and deISGylating activities. However, in transgenic
mice, recombinant chimeric Sindbis viruses, and trans-
fected cells, we found that viral OTU domain-containing
proteases have significant effects on Ub- and ISG15-de-
pendent host processes of known importance for innate
immunity. We therefore conclude that these proteins
have bona fide immune evasion properties. It will be inter-
esting to further investigate the activities of these and
other viral proteases that target Ub- and ISG15-depen-
dent processes during viral infection.
EXPERIMENTAL PROCEDURES
Expression Plasmids
Plasmids pCAGGS-6HismISG15, pCAGGS-hUBE1L-HA, pFLAGCMV2-
UbcM8, and pcDNA3.1-UbcM8 were provided by Dong-Er Zhang
(Scripps Research Institute, La Jolla, CA) (Giannakopoulos et al., 2005).
Herc5 was provided by Motoaki Ohtsubo (Kurume University, Fukuoka-
ken, Japan). pcDNA 3.1+-HA-Ub was provided by Dr. Domenico Tortor-
ella (Mount Sinai School of Medicine, NY) (Treier et al., 1994). Peak10-
Flag-A20 plasmid was provided by Dr. Adrian Ting (Mount Sinai School
of Medicine). The construction of all other plasmids is described in the
Supplemental Experimental Procedures.
Antibodies
Antibodies against Flag (M2 and rabbit polyclonal, Sigma, St. Louis,
MO), HA (HA.7 [Sigma] HA.11 [Covance Research, Berkeley, CA]),
Ub (P4D1, Cell Signaling, Danvers, MA,) NF-kB p65 (F-6, Santa Cruz
Biotech, Santa Cruz, CA), and actin (AC-74, Sigma) were used follow-
ing manufacturer’s protocol. Anti-mouse ISG15 monoclonal (3C2 and
2D12) and polyclonal antibodies (Lenschow et al., 2005) and antiserum
recognizing EAV-nsp2 (Snijder et al., 1994) have been previously
described.
Purification of CCHFV L(1–169) from E. coli
BL-21 cells (Stratagene, La Jolla, CA) were transformed with pGEX-
L(1–169) or pGEX-L(1–169)1A CCHFV, cultured to an OD600 of 0.6 in
2xYT medium and induced for 6 hr at 30Cwith 0.1 mM IPTG. Bacteria
were resuspended in lysis buffer (50 mM Tris-HCl, 5 mM EDTA, 1 mM
DTT, 200 mM NaCl, and 0.1% NP-40), and purification of the GST fu-
sion proteins was performed using GSH Sepharose resin (Amersham)
according to the manufacturer’s protocol. GST was cleaved using
PreScission Protease (Pharmacia, Uppsala, Sweden) in cleavage
buffer (50 mM Tris-HCl [pH 7.6], 150 mM NaCl, 1 mM EDTA, and
1 mM DTT).
Assays for DeISGylation in Cultured Cells
Initially, 293T cells cultured in 12-well dishes were cotransfected with
0.4 mg of pCAGGS-6HismISG15, 0.4 mg of pCAGGS-hUBE1L-HA, and
0.2 mg of pFLAGCMV2-UbcM8 along with OTU domain expression
plasmids or empty pCAGGS plasmid using Lipofectamine 2000. In
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subsequent experiments testing eukaryotic and viral OTU constructs,
293T cells in 12-well dishes were cotransfected with OTU domain
expression plasmids and 0.5 mg pCAGGS-6His mISG15, 0.5 mg
pCAGGS-mUBE1L-HA, 0.5 mg of plasmid encoding Herc5, and
0.2 mg pFLAGCMV2 UbcM8 or pCDNA3.1-UbcM8. Twenty-four hours
posttransfection, cells were lysed in Laemmli sample buffer, boiled,
and analyzed by immunoblot using anti-ISG15 mAb 3C2 as previously
described (Lenschow et al., 2005). Each transfection experiment was
performed a minimum of three times.
Assay for Deubiquitination in Cultured Cells
293T cells cultured in 12-well dishes were cotransfected with 0.5 mg of
pcDNA3.1-HA-Ub and various OTU domain expression plasmids or
empty pCAGGS plasmid using Lipofectamine 2000. Twenty-four
hours posttransfection, the cells were lysed in Laemmli sample, boiled,
and immunoblotted with anti-HA antibody. Each transfection experi-
ment was performed a minimum of three times.
Generation of ISG15 Conjugates
Fourteen 10 cm dishes of 293T cells were transfected with 6 mg
pCAGGS-6HismISG15, 3 mg pCAGGS-hUBE1L-HA, and 3 mg
pFLAGCMV2-UbcM8. Twenty-four hours later, cells were harvested,
resuspended in 20 mM Tris-HCl (pH 8.0) with 300 mM NaCl, and lysed
by three cycles of freeze-thaw. Lysates were centrifuged for 15 min at
14,000 rpm. His-tagged ISG15 conjugateswere purified over a His-Se-
lect Spin Column (SIGMA) following the manufacturer’s directions.
Column-bound conjugates were washed extensively with washing
buffer (20 mM Tris-HCl [pH 8.0], 300 mM NaCl, and 5 mM Imidazole)
and eluted with 20 mM Tris-HCl (pH 8.0), 300 mM NaCl, and
250 mM Imidazole. Protein concentration was measured by Bradford
assay (Bio-Rad).
In Vitro Deconjugation Assays
K48 Ub2–7, K
63 Ub3–7, SUMO-22–8, SUMO-32–8, pro-ISG15, pro-Nedd8,
pro-SUMO-1, USP5/Isopeptidase T, NEDP1, UBP43, A20CD, and
His6-SENP2CD were purchased from Boston Biochem (Cambridge,
MA). All reactions were performed in 50 mM Tris-HCl (pH 7.6), 5 mM
MgCl2, and 2 mM DTT at 37C for 2 hr. Serial 10-fold dilutions of
L(1–169) or L(1–169)1A (ranging from 2.5 mM to 2.5 nM) were incubated
with either 2.5 mg Ub chains or SUMO chains; 2.5 mg pro-ISG15, pro-
Nedd8, or pro-SUMO-1; 10 ml Ubp43/ lysate; or 3 mg of 6HisISG15
conjugates. Positive control for deconjugation was incubation with
100 mM USP5 (Ub), SENP2CD (SUMO), NEDP1 (Nedd8), or UBP43
(ISG15). Negative control was incubation of chains or conjugates in as-
say buffer alone. Reactions were terminated by addition of Laemmli
sample buffer and separated by SDS-PAGE electrophoresis on
a 4%–20% gradient gel (BioRad). Proteins were visualized by
SimplyBlue Safestain (Invitrogen) staining (Ub and SUMO) or by anti-
ISG15 western blot.
Viruses
Sindbis viruseswere generated froma cDNAclone by in vitro transcrip-
tionandRNA transfectionofBHK-21cells aspreviouslydescribed (Lev-
ine et al., 1996; Lenschow et al., 2005). Recombinant virus stocks were
produced and titered on BHK-21 cells as previously described (Len-
schow et al., 2005). Sindbis virus AR86was a kind gift of Dr.Mark Heise
(University of North Carolina, Chapel Hill) (Heise et al., 2000).
NF-kB Reporter Gene Assay
293T cells were cotransfected with 3.3-fold dilutions (starting at
100 ng) of A20, CCHFV-L(1–169), CCHFV-L(1–169)2A, EAV-nsp2N,
or empty plasmid along with the firefly luciferase gene construct under
the control of the NF-kB-binding sites) (Wang et al., 2000) and pRL-TK
(Renilla luciferase; Promega, WI). The total amount of transfected DNA
was kept constant by adding the pCAGGS empty vector. Twenty-four
hours posttransfection, the cells were stimulated with TNFa (10 ng/ml)
for 6 hr, and luciferase activities were measured using the Dual-Lucif-
erase Reporter (DLR) Assay System (Promega). Final NF-kB luciferase
values were normalized with the Renilla luciferase values as internal
control.
Immunofluorescence
Two hundred nanograms of empty plasmid or Flag-tagged L(1–169)
and L(1–169)2A were transfected into A549 cells. Twenty-four hours
later, cells were stimulatedwith 10 ng/ml TNFa for 2 hr. Cells were fixed
and permeabilized for 30 min at room temperature with 2.5% formal-
dehyde and 0.5% Triton X-100, washed extensively with PBS, and
stained with anti-p65 and anti-Flag antibodies. Following PBSwashes,
cells were stained with anti-mouse (p65) or anti-rabbit (Flag) and
secondary antibodies, and then mounted in medium containing an
antifade reagent. Nuclear localization of p65 was scored in 100 to
400 transfected cells for each experimental condition.
Mouse Studies
IFNabR/mice on the 129/SV/Pas background were initially obtained
fromM. Aguet, Swiss Institute of Experimental Cancer Research (Epa-
linges, Switzerland) (Behr et al., 2001; Dunn et al., 2005). CCHFV-L(1–
1325) transgenic mice were generated at the WUSM Pathology Micro-
injection Core by microinjecting a linearized construct derived from
pCAGGS-HA-L(1–1325) into B6 oocytes. Oocytes were implanted
into pseudopregnant mice, and resulting litters were genotyped using
PCR (primer sequences available upon request). Individual embryo
MEFs from transgenic lines 1836, 1854, and 2929 were generated as
described previously (Weck et al., 1999). Uninfected transgenic brain
was homogenized in 1 ml of DMEM with protease inhibitors using
100 ml 1.0 mm diameter zirconia-silica beads in a MagNa Lyser (Roche,
Indianapolis, IN). To assess transgene expression, 43 105MEFsor 12ml
of brain homogenate were immunoblotted with HA.11 and anti-actin
antibodies. Eight- to ten-week-oldmale IFNabR/mice were infected
subcutaneously (s.c.) in the left hind footpad with 53 106 PFU of virus
diluted in 50 ml of Hank’s balanced salt solution (HBSS). Four- to five-
week old L(1–1325) transgenic mice were infected s.c. in the left hind
footpad with 5000 PFU of Sindbis virus AR86 diluted in 50 ml of HBSS.
Mice were bred and maintained at Washington University School of
Medicine in accordance with all federal and university guidelines.
Statistical Analysis
All data were analyzed with Prism software (GraphPad, San Diego,
CA). Survival data were analyzed by the log-rank (Mantel-Haenzsel)
test, with death as the primary variable. Single-step growth curves
were analyzed by one-way analysis of variance (ANOVA).
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures and two supplemental figures and can be found with this article
online at http://www.cellhostandmicrobe.com/cgi/content/full/2/6/
404/DC1/.
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